Clinical Trial Results:
Estudio aleatorizado en fase 2 de Folfox o Folfiri con AG-013736 o Bevacizumab en pacientes con cáncer colorrectal metastásico después del fracaso a una pauta de primera línea con irinotecan u oxaliplatino.
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line Regimen
Summary
|
|
EudraCT number |
2007-006283-30 |
Trial protocol |
ES CZ FR IT BE |
Global completion date |
12 Apr 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Mar 2016
|
First version publication date |
11 Feb 2015
|
Other versions |
|
Summary report(s) |
A4061034 EU Posting |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.